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Anatomical Exclusion
for Renal Denervation
Are We Putting the Cart Before the Horse?*
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Matthew C. Bunte, MD
Cleveland, Ohio
The race is underway to develop a safe and widely applicable
endovascular solution for renal sympathetic denervation
(RDN). Important limitations of ﬁrst-generation RDN
devices have spurred innovative new solutions in the form
of unique endovascular technologies, including many that
are currently under investigation in clinical trials (1).
Certainly, these developments add encouragement to the
provocative, if not limited, randomized treatment results of
the SYMPLICITY HTN-2 (Renal Sympathetic Denerva-
tion in Patients With Treatment-Resistant Hypertension)
trial (2). Even if further randomized clinical experience
strengthens the concept of RDN, there remain important
considerations that are likely to limit broader application of
this technology.See page 187Among other restrictions, renal anatomy must be
favorable to permit satisfactory treatment delivery. Spe-
ciﬁcally, the current iteration of most catheter-based
RDN systems require a renal artery diameter of 4 mm
(3 mm for Vessix, Boston Scientiﬁc, Inc., Natick,
Massachusetts), a treatable vessel length of >20 mm, and
no signiﬁcant accessory arterial branches (supplying more
than 25% of blood ﬂow) to the kidney. Renal artery
anatomy can be quite variable and may limit applicability
of RDN if current anatomic eligibility requirements do
not change with improvements in technology. Indeed,
nearly 16% of the 190 patients screened in the SYM-
PLICITY HTN-2 trial were excluded based on anatomic
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Rimoldi et al. (3) present an observational analysis of 934
consecutive subjects with resistant and nonresistant hyper-
tension who underwent renal angiography at the discretion
of their provider. Angiographic results were categorized by
deﬁnitions of anatomic eligibility according to current renal
denervation trials using the Symplicity catheter system
(Medtronic, Mountain View, California). A group of 8
experienced physicians performed quantitative measure-
ments of the renal artery diameter and vessel length, among
whom the investigators report a reasonably low level of
intra- and inter-reader variability (3).
Among 934 subjects undergoing renal angiography, 90
(9.6%) patients were excluded due to renal artery stenosis.
Of the remaining 844 eligible patients, only 443 (52%) had
vascular anatomy suitable for RDN. The most common
exclusion from RDN eligibility was vessel length <20 mm
(25%) due to early renal artery bifurcation, followed by
accessory renal arteries (19%), and renal artery diameter
<4 mm (15%). Among the 117 patients retrospectively
identiﬁed to have resistant hypertension, anatomic eligibility
for renal denervation was 53%. Interestingly, the in-
vestigators found no differences in eligibility rates based on
whether or not the patient had resistant or nonresistant
hypertension.
This study highlights the anatomic limitations of current
catheter-based renal denervation techniques, but a few
points deserve further discussion. First, most renal dener-
vation trials allow accessory renal arteries as long as these do
not perfuse >25% of the ipsilateral renal parenchyma (4).
Whereas some devices (Vessix) allow ablation of these
vessels if the diameter is >3 mm, current European
consensus documents advocate the absence of polar or
accessory renal arteries (5). Furthermore, a recent small
study showed a signiﬁcantly lesser reduction in blood
pressure in those patients with multiple renal arteries versus
patients with a single main artery (6). The impact of
accessory or polar renal arteries on catheter-based renal
denervation remains under investigation. Second, the cur-
rent randomized trials have excluded eligible vessel length of
<20 mm, however, most clinical trials allow side branches if
the diameter of these vessels is <50% of the main renal
artery (4). Furthermore, with newer generation multielec-
trode devices, it is not clear whether 20 mm of eligible vessel
length is actually necessary. Currently, there is little corre-
lation between the number of ablation sites and reduction in
blood pressure. Therefore, much shorter ablation length
may be adequate in the near future. Third, prior to renal
angiography, vasodilatory medications were not adminis-
tered, something that is currently required by most clinical
trials (4). Fourth, the investigators excluded any renal artery
stenosis (according to the European consensus); however,
most trials allow some degree of renal atherosclerosis (<30%
to 50%) (4,5).
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194In summary, renal and carotid catheter-based therapies
to treat hypertension and other conditions such as atrial
ﬁbrillation, ventricular tachycardia, pulmonary hyperten-
sion, metabolic syndrome, and sleep apnea, among others,
are rapidly under development (7). It is exciting to learn
about the current limitations of catheter-based renal
denervation devices; however, we must remain cautious
about putting the cart before the horse when the safety and
efﬁcacy of these interventions has yet to be determined.
Indeed, despite a high prevalence of resistant or uncon-
trolled hypertension, published data are available only on
100 patients worldwide who have ever been randomized
(SYMPLICITY HTN-2) to renal denervation versus
control group (2). Furthermore, despite limited level 1 data,
there have been 2 expert consensus documents related to
catheter-based renal denervation, and 4 devices have already
gained European approval and are clinically available
outside the United States (5,8)! Clearly, there is much we
must learn before widespread use of catheter-based renal
denervation.
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